“`html
Summary of Clinical Trial Findings
Recent research in prostate cancer trials has focused on finding intermediate clinical endpoints (ICEs) that can provide reliable indicators of overall survival (OS).
Practical Solutions and Value
- Metastasis-free survival has been identified as a strong ICE for localized prostate cancer, offering a practical and cost-effective measure for assessing treatment effectiveness.
- In advanced prostate cancer, ICEs such as radiological and clinical progression-free survival have shown promise in the context of metastatic hormone-sensitive PCa, potentially allowing for earlier introduction of new treatment methods.
- Using ICEs can help reduce trial costs and expedite the evaluation of new treatments, ultimately benefiting patients by facilitating quicker access to potentially effective therapies.
“`
